Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06929832

Post-Market Evaluation of Active Thrombectomy and Proximal Aspiration During Lower Extremity Tibial Interventions

Post-Market Evaluation of Active Thrombectomy and Proximal Aspiration during Lower Extremity Tibial Interventions

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

This is a prospective, multi-center, non-randomized, open label, single arm post-market clinical study to gather data on the use of the Protexus catheter for temporary blood vessel occlusion while standard of care treatment with other therapeutic devices is conducted in patients undergoing infrapopliteal treatment for peripheral arterial disease (PAD).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is at least 18 years of age
  • Subject or authorized representative has signed a written Informed Consent
  • Subject is willing to comply with the protocol requirements
  • Rutherford classification 4-6
  • Planned intervention of the native infrapopliteal arteries using balloon angioplasty, atherectomy, and endovascular procedures.
  • Reference vessel diameter for intended location of the distal tip funnel deployment for the Protexus catheter is ≥3.5mm and ≤6.0mm by visual estimate
  • Inflow arteries have ≤30% stenosis. Inflow arteries can be treated at the time of the study procedure to achieve ≤30% stenosis

Exclusion criteria

  • Prior intervention within 30 days of treatment in the planned deployment site for the Protexus catheter
  • Presence of a stent in the planned deployment site for the Protexus catheter
  • Has perforation, dissection, or other injury of the access vessel or Protexus catheter deployment site requiring additional stenting or surgical intervention before enrollment
  • History of bleeding diathesis or coagulopathy and unable to receive standard anticoagulation during the index procedure
  • Acute limb ischemia defined as onset of symptoms within two weeks of the planned intervention
  • Inflow arteries have >30% stenosis after treatment at the time of the study procedure
  • Pregnant female subject or subject that has a positive pregnancy test within the previous 7 days
  • Known hypersensitivity or allergy to nitinol
  • Target blood vessels are infected, have extreme tortuosity, or are occluded with calcified material

Treatment and study plan

Primary outcomes

  1. Primary Endpoint

    Time frame: 30 Days

    The incidence, type, and severity of Protexus related major adverse events (MAEs) through 30-days defined as:

    • Death or organ injury
    • Thrombosis, pseudo-aneurysm, dissection (grade C or greater by visual assessment) or clinical perforation at the Protexus device location
    • Angiographically evident flow limiting distal embolization

Study contacts

Contact information is provided by the study sponsor or research team.

Ryan Balko

CONTACT

[email protected]

612-251-2526

Sponsors and collaborators

Lead sponsor

Protexa Endovascular, Inc.

Industry

Registry information

Acronym: Protexus 1

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Apr 16, 2025
Registry last updated
Apr 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.